Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides

Cancers

Michèle Allouche¹  Stéphane Galiacy¹  Arthur Aubry² 

[1] INSERM, UDEAR, UMR1056, F-31300 Toulouse, France;Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada;

关键词: anaplastic lymphoma kinase;    ALK;    tyrosine kinase;    dependence receptor;    proapoptotic peptides;    tyrosine kinase inhibitor;    anaplastic large cell lymphoma;    non-small-cell lung cancer;    neuroblastoma;    targeted therapy;   

DOI  :  10.3390/cancers11030275

来源: DOAJ

【 摘 要 】

ALK is a receptor tyrosine kinase, associated with many tumor types as diverse as anaplastic large cell lymphomas, inflammatory myofibroblastic tumors, breast and renal cell carcinomas, non-small cell lung cancer, neuroblastomas, and more. This makes ALK an attractive target for cancer therapy. Since ALK⁻driven tumors are dependent for their proliferation on the constitutively activated ALK kinase, a number of tyrosine kinase inhibitors have been developed to block tumor growth. While some inhibitors are under investigation in clinical trials, others are now approved for treatment, notably in ALK-positive lung cancer. Their efficacy is remarkable, however limited in time, as the tumors escape and become resistant to the treatment through different mechanisms. Hence, there is a pressing need to target ALK-dependent tumors by other therapeutic strategies, and possibly use them in combination with kinase inhibitors. In this review we will focus on the therapeutic potential of proapoptotic ALK-derived peptides based on the dependence receptor properties of ALK. We will also try to make a non-exhaustive list of several alternative treatments targeting ALK-dependent and independent signaling pathways.

【 授权许可】

Unknown